Here are the 10-Q quarterly reports from GeoVax Labs, Inc. Warrants (GOVXW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GOVXW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GOVXW filings page.
GeoVax Labs reported a first-quarter 2026 net loss of $5.26 million, similar to the prior year, but with a much weaker balance sheet. Revenue from government contracts fell to zero after termination of a BARDA contract that had generated $1.64 million in Q1 2025.
Research and development spending was $3.90 million and general and administrative expenses were $1.37 million, both lower than a year earlier as certain program and investor-relations costs declined. Cash and cash equivalents dropped to $1.27 million as of March 31 2026, with working capital of $0.14 million.
The company financed operations through equity offerings, an at-the-market program, and warrant exercises raising roughly $1.72 million in the quarter, plus additional inducement-related warrant exercises in May. Management states existing cash is expected to fund operations only into June 2026 and discloses substantial doubt about GeoVax’s ability to continue as a going concern.